Abstract: FR-PO0330
Successful Implementation of KidneyIntelX in a Large Integrated Health System for Risk-Based Management of Diabetic Kidney Disease
Session Information
- Diabetic Kidney Disease: Progression, Predictive Tools, Therapeutics, and Outcomes
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 702 Diabetic Kidney Disease: Clinical
Authors
- Tokita, Joji E., Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Lam, David W., Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Rathi, Shivani, Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Fleming, Fergus, Renalytix AI Inc, New York, New York, United States
- Donovan, Michael J., Renalytix AI Inc, New York, New York, United States
Background
Diabetic kidney disease (DKD) is underdiagnosed and under-treated, compounded by suboptimal risk stratification and delays in the initiation of guideline-directed medical therapy. KidneyIntelXTM, a precision medicine test, combines biomarkers and clinical data to predict progressive DKD. We describe its implementation within the Mount Sinai Health System DKD Care Pathway with the objective to improve care through sustainable adoption and compliance.
Methods
A multi-disciplinary team identified barriers to adoption and developed novel solutions including preemptive patient identification, provider education, operational workflows, and access to centralized specialty services. Implementation included three overlapping and iterative strands: Planning, Execution, and Sustainability.
Results
In planning, integration of the test into electronic health records enabled streamlined patient identification, test ordering, and reporting. Education and training to promote DKD awareness and the role of early risk stratification for targeted interventions was delivered across 53 practice locations, comprised of Primary Care (63%) and specialty service providers (37%). Sustainability was observed with over 9,000 KidneyIntelX tests reported since March 2021. A central team, including pharmacists, facilitated patient-level compliance driven by the test result. Finally, continuous dissemination of data relating to operational metrics, clinical performance, and the effective use of risk-assessment in DKD were key drivers in promoting long-term program sustainability (Figure).
Conclusion
KidneyIntelX has been successfully introduced into a complex healthcare system, demonstrating sustained effectiveness and impact. Risk-guided care was observed, notable in the escalation of SGLT2i therapy in higher-risk DKD patients. This can be a reproducible framework for integrating precision medicine tools into routine care to improve outcomes for other chronic conditions.
Funding
- Commercial Support – Renalytix